|
Volumn 304, Issue 5676, 2004, Pages 1458-1461
|
A bull's eye for targeted lung cancer therapy
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CETUXIMAB;
EPIDERMAL GROWTH FACTOR RECEPTOR;
ERLOTINIB;
GEFITINIB;
ANTINEOPLASTIC AGENT;
ENZYME INHIBITOR;
EPIDERMAL GROWTH FACTOR;
LIGAND;
QUINAZOLINE DERIVATIVE;
CANCER;
DISEASE TREATMENT;
CANCER CHEMOTHERAPY;
CANCER PATIENT;
COLON CANCER;
DRUG TARGETING;
ENDOCYTOSIS;
GENE SEQUENCE;
HUMAN;
HUMAN GENOME;
LUNG CANCER;
PRIORITY JOURNAL;
PROTEIN TARGETING;
REVIEW;
TREATMENT OUTCOME;
ADENOCARCINOMA;
AMINO ACID SUBSTITUTION;
CHEMISTRY;
CONTROLLED CLINICAL TRIAL;
DRUG ANTAGONISM;
GENE DELETION;
GENETICS;
JAPAN;
LUNG NON SMALL CELL CANCER;
LUNG TUMOR;
METABOLISM;
MUTATION;
NOTE;
PHOSPHORYLATION;
PROTEIN TERTIARY STRUCTURE;
PROTO ONCOGENE;
SMOKING;
UNITED STATES;
ADENOCARCINOMA;
AMINO ACID SUBSTITUTION;
ANTINEOPLASTIC AGENTS;
CARCINOMA, NON-SMALL-CELL LUNG;
CONTROLLED CLINICAL TRIALS;
ENZYME INHIBITORS;
EPIDERMAL GROWTH FACTOR;
GENES, ERBB-1;
HUMANS;
JAPAN;
LIGANDS;
LUNG NEOPLASMS;
MUTATION;
PHOSPHORYLATION;
PROTEIN STRUCTURE, TERTIARY;
QUINAZOLINES;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
SEQUENCE DELETION;
SMOKING;
TREATMENT OUTCOME;
UNITED STATES;
|
EID: 2642570917
PISSN: 00368075
EISSN: None
Source Type: Journal
DOI: 10.1126/science.1099578 Document Type: Review |
Times cited : (68)
|
References (7)
|